BGES Bio Bridge Science Inc (CE)

According to a joint report issued by UNAIDS and WHO, an estimated 39.5 million people globally are living with HIV and an estimated 4.3 million individuals were newly infected during 2006. An overwhelming proportion of the people living with HIV are in Sub-Saharan Africa where the estimated number of people infected is 24.7 million. The number of people estimated to be living with HIV is 1.2 million in the U.S., 650,000 in China, and 17,000 in Japan. China's Ministry of Health expressed recently that the number of people officially reported as infected by HIV has risen 27.5 percent since the beginning of 2006 according to Xinhua. To curb the global spread of HIV, experts believe that a vaccine is needed to fight HIV infection. Bio-Bridge Science, Inc. (OTCBB: BGES) is in development of a promising new HIV Vaccine that is expected to enter clinical trials in 2007 in China. The vaccine targets infection in mucosal tissues, which is a unique approach to prevent and treat HIV infection. The pre-clinical trials have been done in China and suggest that the vaccine is safe and effective in the treatment and prevention of HIV.�Bio-Bridge is dedicated to developing this HIV therapeutic and preventive vaccine to fight HIV/AIDS. Links: http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf http://news3.xinhuanet.com/english/2006-11/30/content_5414604_1.htm Forward Looking Statements: This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information. According to a joint report issued by UNAIDS and WHO, an estimated 39.5 million people globally are living with HIV and an estimated 4.3 million individuals were newly infected during 2006. An overwhelming proportion of the people living with HIV are in Sub-Saharan Africa where the estimated number of people infected is 24.7 million. The number of people estimated to be living with HIV is 1.2 million in the U.S., 650,000 in China, and 17,000 in Japan. China's Ministry of Health expressed recently that the number of people officially reported as infected by HIV has risen 27.5 percent since the beginning of 2006 according to Xinhua. To curb the global spread of HIV, experts believe that a vaccine is needed to fight HIV infection. Bio-Bridge Science, Inc. (OTCBB: BGES) is in development of a promising new HIV Vaccine that is expected to enter clinical trials in 2007 in China. The vaccine targets infection in mucosal tissues, which is a unique approach to prevent and treat HIV infection. The pre-clinical trials have been done in China and suggest that the vaccine is safe and effective in the treatment and prevention of HIV. Bio-Bridge is dedicated to developing this HIV therapeutic and preventive vaccine to fight HIV/AIDS. Links: http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf http://news3.xinhuanet.com/english/2006-11/30/content_5414604_1.htm Forward Looking Statements: This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information.